Department of Clinical Medicine and Surgery, 'Federico II' University of Naples, Naples, Italy; GI Physiology Unit, University College London Hospital, London, UK.
Department of Physiology and Pharmacology, `Vittorio Erspamer', La Sapienza University of Rome, Rome, Italy.
Curr Opin Pharmacol. 2018 Dec;43:81-86. doi: 10.1016/j.coph.2018.08.009. Epub 2018 Sep 12.
The evolving policies regarding the use of therapeutic Cannabis have steadily increased the public interest in its use as a complementary and alternative medicine in several disorders, including inflammatory bowel disease. Endocannabinoids represent both an appealing therapeutic strategy and a captivating scientific dilemma. Results from clinical trials have to be carefully interpreted owing to possible reporting-biases related to cannabinoids psychotropic effects. Moreover, discriminating between symptomatic improvement and the real gain on the underlying inflammatory process is often challenging. This review summarizes the advances and latest discovery in this ever-changing field of investigation, highlighting the main limitations in the current use of these drugs in clinical practice and the possible future perspectives to overcome these flaws.
随着治疗性大麻使用政策的不断演变，公众对其在包括炎症性肠病在内的多种疾病中的应用作为补充和替代医学的兴趣日益浓厚。内源性大麻素既是一种有吸引力的治疗策略，也是一个引人入胜的科学难题。由于与大麻素的精神作用相关的可能报告偏倚，必须仔细解释临床试验的结果。此外，区分症状改善和潜在炎症过程的真正获益通常具有挑战性。本文综述了该研究领域的最新进展和最新发现，强调了目前在临床实践中使用这些药物的主要局限性，以及克服这些缺陷的可能未来前景。
